Status:
RECRUITING
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
Lead Sponsor:
Psoriasis Treatment Center of Central New Jersey
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
Detailed Description
30 subjects will be treated with increasing doses of Narrowband Ultraviolet phototherapy three times weekly for 12 weeks. Patients will then be evaluated every 6 weeks through week 36 to determine mai...
Eligibility Criteria
Inclusion
- Male or female adults ≥ 18 years of age.
- Diagnosis of chronic plaque-type psoriasis for at least 6 months
- Moderate to Severe plaque psoriasis as defined by BSA ≥10 PASI ≥12 IGA ≥3
- Able to give written informed consent prior to performance of any study related procedures
- Subject is able to attend Narrowband UVB phototherapy sessions three times a week and all other protocol specified visits
- Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination.
Exclusion
- Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis
- History of photosensitivity
- Subject has used ustekinumab and/or anti-IL-17 biologic therapy within 24 weeks or other experimental or commercially available biologic immune modulator(s) within 12 weeks prior to the first IP dose.
- Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
- Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin, apremilast and cyclosporine).
- Patient used topical therapies to treat within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).
- Initiated within 3 months, planned initiation of, or changes to, concomitant medications that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors ) during the trial
- Active infections requiring antibiotics in the 2 weeks prior to Baseline
- Patient received UVB phototherapy within 4 weeks of Baseline.
- Patient received PUVA phototherapy within 4 weeks of Baseline.
Key Trial Info
Start Date :
November 7 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03392337
Start Date
November 7 2017
End Date
January 1 2020
Last Update
January 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Elise Nelson
East Windsor, New Jersey, United States, 08520